Heart failure & cardiomyopathies
Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial
Authors' conclusion
These results indicate that mitiperstat was safe and well tolerated but did not improve symptoms or exercise function in chronic heart failure with preserved or mildly reduced ejection fraction.
Study context
- Population
- Patients with HF and EF >40%45% women
- Participants
- 711 patients
- Comparison
- Mitiperstat vs placebo
- Primary endpoint
- Co-primary: KCCQ Total Symptom Score (Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS)) and 6-minute walk distance (6MWD)
- Follow-up
- 16 weeks
Methodological detailsmulticenter, double-blind, placebo-controlled, three-arm, parallel-group, phase 2b
- Multicenter
- Double-blind
- Placebo-controlled
- Three-arm
- Parallel-group
- Phase 2b
Primary result
As reported in the abstract
Mitiperstat (pooled doses) vs PlaceboPlacebo-corrected difference in mean change from baseline, points (95% CI)P value
KCCQ-TSS
−1.4(−3.9 to 1.2)
P = 0.29Mitiperstat (pooled doses) vs PlaceboPlacebo-corrected difference in mean change from baseline, m (95% CI)P value
6MWD
3.8(−3.1 to 10.8)
P = 0.28Secondary outcomes
Natriuretic peptides, inflammatory markers (up to 48 weeks), echocardiographic parameters (up to 24 weeks)
- No improvement in any secondary endpoint
Safety
- Maculopapular rash — Placebo
- 0.4%
- Maculopapular rash: Mitiperstat 3.6%
Adverse and serious adverse events, including infections
- Similar among groups (except maculopapular rash)
Original publication
Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial. Nat Med. Published 9 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →